aTyr Pharma, a San Diego-based biotherapeutics company, has appointed Sanuj Ravindran as Chief Business Officer. In this role, Ravindran will lead the firm’s corporate development and strategy efforts, including the planning and execution of strategic growth initiatives.
“As we continue to realize the promise of Physiocrines, harnessing the body’s natural immune processes to develop new treatments for rare diseases, we are thrilled with the addition of Ravindran to our team,” stated John Mendlein, CEO of aTyr Pharma. “Ravindran brings valuable experience from nearly 15 years working in life sciences corporate development and investing, and will be a critical leader for aTyr Pharma in its next chapter of growth,” he added.
Ravindran joined as Senior Vice President and Global Head for Corporate Development from The Medicines Company in New Jersey. He played a key role in the company’s global corporate development, strategic planning, and business development activities for acute and intensive care medicine. Previously, he spent 10 years as a life sciences venture capital investor for Asian Healthcare Fund, Radius Ventures and Burrill & Company.
Founded in 2005, aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company’s lead candidate, Resolaris™, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component, is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD).